Table 6. Historical OS and PFS for patients with advanced ovarian cancer.
| First author | Journal | Patients | Drugs | PFSa | OSa |
|---|---|---|---|---|---|
| Conte PF | J Clin Oncol (1986) 4: 965–969 | 125 | CDDP+CTX | 12.6 | 22.7 |
| CDDP+CTX+Doxo | 13.3 | 26.7 | |||
| Alberts DS | J Clin Oncol (1992) 10: 706–710 | 342 | CDDP+CTX | N/A | 17.4 |
| CBDCA+CTX | N/A | 20 | |||
| Swenerton K | J Clin Oncol (1992) 10: 718–721 | 447 | CDDP+CTX | 13.1 | 23.3 |
| CBDCA+CTX | 13.5 | 25.7 | |||
| Rothenberg ML | J Clin Oncol (1992) 10: 727–734 | 50 | CDDP+CTX+RT | N/A | 23.4 |
| McGuire WP | N Engl J Med (1996) 334: 1–6 | 235 | CDDP+CTX | 13 | 24 |
| CDDP+PTX | 18 | 36 | |||
| Alberts DS | N Engl J Med (1996 Dec 26) 335(26): 1950–1955. | 546 | CDDP+CTX | 23.8 | 49 |
| CDDP+CTX | 18.3 | 41 | |||
| ICON | Lancet (1998) 352: 1571–1576. | 1526 | CBDCA | 15.5 | 33 |
| CPPD+CTX+Doxo | 17 | 33 | |||
| Muggia FM | J Clin Oncol (2000 Jan) 18(1): 106–115. | 648 | CDDP | 16.4 | 30.2 |
| PTX | 10.8 | 25.9 | |||
| CDDP+PTX | 14.1 | 26.3 | |||
| Markman M | J Clin Oncol (2001 Feb 15) 19(4): 1001–1007 | 462 | CDDP+PTX | 22 | 52 |
| CBDCA+PTX+CDDP | 28 | 63 | |||
| ICON | Lancet (2002 Aug 17) 360(9332): 505–515 | 2074 | CBDCA+PTX | 17.3 | 36.1 |
| CPPD+CTX+Doxo | 16.1 | 35.4 | |||
| Du Bois A | J Natl Cancer Inst (2003 Sep 3) 95(17): 1320–1329. | 798 | CBDCA+PTX | 17.2 | 43.3 |
| CDDP+PTX | 19.1 | 44.1 | |||
| Ozols RF | J Clin Oncol (2003 Sep 1) 21(17): 3194–3200 | 792 | CBDCA+PTX | 20.7 | 57.4 |
| CDDP+PTX | 19.4 | 48.7 | |||
| Vasey PA | J Natl Cancer Inst (2004 Nov 17) 96(22): 1682–1691 | 1077 | CBDCA+PTX | 14.8 | N/A |
| CBDCA+DTX | 15 | N/A | |||
| Pfisterer J | J Natl Cancer Inst (2006 Aug 2) 98(15): 1036–1045. | 1308 | CBDCA+PTX | 18.5 | 43.1 |
| CBDCA+PTX+TPT | 18.2 | 44.5 | |||
| du Bois A | J Clin Oncol (2006 Mar 1) 24(7): 1127–1135. | 1282 | CBDCA+PTX | 17.9 | 41 |
| CBDCA+PTX+Epi | 18.4 | 45.8 | |||
| Bookman MA | J Clin Oncol (2006) ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5002 | 4312 | CBDCA+PTX | 16.1 | 40 |
| CBDCA+PTX+Gem | 16.4 | 40.4 | |||
| CBDCA+PTX+Doxo | 16.4 | 42.8 | |||
| CBDCA+PTX+TPT | 15.3 | 39.1 | |||
| CBDCA+PTX+Gem | 15.4 | 40.2 | |||
| Armstrong DK | N Engl J Med (2006 Jan 5) 354(1): 34–43 | 415 | CDDP+PTX | 23.8 | 65.6 |
| CDDP+PTX | 18.3 | 49.7 |
Abbreviations: CBDCA=carboplatin; CDDP=cisplatin; CTX=cyclophosphamide; Doxo=doxorubicin; DTX=docetaxel; Epi=epirubicin; Gem=gemcitabine; OS=overall survival; PFS=progression-free survival; PTX=paclitaxel; RT=radiotherapy; TPT=topotecan.
a
PFS and OS are expressed in months.